Upstream Bio (NASDAQ:UPB) Cut to In-Line at Evercore

Evercore downgraded shares of Upstream Bio (NASDAQ:UPB) from an outperform rating to an in-line rating in a research note published on Friday morning, Marketbeat Ratings reports. Evercore currently has $15.00 target price on the stock.

Other equities analysts have also issued reports about the stock. Lifesci Capital assumed coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price objective on the stock. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Upstream Bio presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Upstream Bio Stock Performance

Shares of NASDAQ:UPB opened at $8.67 on Friday. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.68. The stock has a market capitalization of $471.82 million, a P/E ratio of -3.25 and a beta of 3.00. The business has a 50-day moving average price of $15.93 and a two-hundred day moving average price of $21.40.

Upstream Bio (NASDAQ:UPB) last issued its earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. The business had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.52 million. As a group, equities analysts predict that Upstream Bio will post -4.3 EPS for the current year.

Institutional Trading of Upstream Bio

Institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Upstream Bio during the 4th quarter worth approximately $29,000. Torren Management LLC acquired a new position in Upstream Bio during the fourth quarter valued at approximately $30,000. BNP Paribas Financial Markets increased its stake in Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares in the last quarter. Legal & General Group Plc increased its stake in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Upstream Bio by 95.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock worth $39,000 after purchasing an additional 1,736 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.